Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
XGN
STRONG SELLExagen Inc. · Healthcare · United States · $113M · Avg Vol: $1M/d
17
StockRankGet insider-trade alerts
Q
35
V
28
M
35
P/E (TTM)
—
ROE
-193.6%
D/E
1.9x
Dividend %
—
Loading 1Y...
PRICE (1Y)-5.8%
SMA 50SMA 200
Close
$4.40
RSI (14)
42.7
52W High
$12.23
From 52W High
0.4%
SCORE BREAKDOWN
Quality
35
ROIC
-34.3%21.4
ROE
-193.6%4.1
GP/Assets
68.7%94.4
Op. Margin
-19.7%26.9
FCF/Assets
-24.3%14.9
Piotroski
239.0
Int. Cover
-3.0x31.1
D/E Ratio
1.88x6.2
Current Ratio
3.47x59.2
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-10.0x25.0
P/FCF
—N/A
P/B
7.8x15.4
P/S
1.7x72.8
Div Yield
—N/A
Momentum
35
52W High %
36%12.3
RS 6M
-12%57.6
SMA 50/200
0.83x24.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+52%55.8
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$113M
P/E (Forward)
-10.9x
Gross Margin
58.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| XGN | Exagen Inc.(you) | $113M | 17 | STRONG SELL |
| IMDX | Insight Molecular Diagnostics Inc. | $153M | 7 | STRONG SELL |
| 950130.KQ | Access Bio, Inc. | $60M | 9 | STRONG SELL |
| BDSX | Biodesix, Inc. | $228M | 38 | HOLD |
| CSTL | Castle Biosciences, Inc. | $749M | 19 | STRONG SELL |
| FLGT | Fulgent Genetics, Inc. | $559M | 27 | SELL |
| MYGN | Myriad Genetics, Inc. | $530M | 35 | SELL |
| FRNM | Freenome, Inc. | $1.2B | 11 | STRONG SELL |
| PSNL | Personalis, Inc. | $1.3B | 24 | SELL |
| WGS | GeneDx Holdings Corp. | $1.8B | 14 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%